Antengene Corporation Limited (722) Price & Analysis

0 Followers

722 Stock Chart & Stats

€0.53

>-€0.01(-1.45%)

At close: Jan 08 4:00 PM EST

€0.53

>-€0.01(-1.45%)

Day’s Range― - ―

52-Week Range€0.29 - €0.85

Previous CloseN/A

Volume0.00

Average Volume (3M)0.00

Market Cap

€269.29M

Enterprise Value€1.68K

Total Cash (Recent Filing)€734.29M

Total Debt (Recent Filing)€257.51M

Price to Earnings (P/E)41.4

Beta0.56

Next Earnings

Mar 19, 2027

EPS Estimate

0.02

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.38

Shares Outstanding679,446,660

10 Day Avg. Volume0

30 Day Avg. Volume0

Financial Highlights & Ratios

PEG Ratio0.35

Price to Book (P/B)3.32

Price to Sales (P/S)20.24

P/FCF Ratio-11.92

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€1.17

Price Target Upside120.13% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)0.05

Revenue Forecast (FY)€88.72M

Bulls Say, Bears Say

Bulls Say

Improving Revenue GrowthThe return to meaningful top-line growth indicates improving commercial traction for approved products and partnerships. Sustained growth could provide operating leverage and broaden the revenue base, although further scale is needed.

Positive Gross ProfitA positive gross margin shows that the company’s products can generate economic value after direct costs. This provides a foundation for future profitability if commercialization expands and operating expenses become more efficient.

Low And Improving LeverageLower leverage reduces fixed financial obligations and preserves flexibility to fund clinical development, regulatory work, and commercialization. This is a structural balance-sheet advantage while the company remains dependent on external capital.

Bears Say

Persistent Operating LossesPersistent operating and net losses show that current commercial scale is insufficient to cover research, development, and corporate costs. Continued losses can constrain investment capacity and increase reliance on financing or partnerships.

Negative Free Cash FlowImproved cash burn is constructive, but materially negative free cash flow means operations are not self-funding. The company must continue using existing capital or obtain new funding to support clinical and commercial programs.

Eroding Capital BaseDeclining equity and assets indicate that accumulated losses are reducing the financial resource base. Unless profitability or external funding improves, this erosion may limit strategic flexibility and weaken resilience across development cycles.

Antengene Corporation Limited News

Antengene Wins Australian Approval to Begin Phase I Trial of Autoimmune Drug ATG-201

Antengene Corporation Limited ( ($HK:6996) ) just unveiled an announcement. Antengene Corporation Limited has secured Human Research Ethics...

7d ago

Antengene Swings to Interim Profit on Licensing-Driven Revenue Surge

The latest update is out from Antengene Corporation Limited ( ($HK:6996) ). Antengene Corporation Limited reported a sharp...

10d ago

Antengene Sets Board Meeting to Approve 2026 Interim Results

Antengene Corporation Limited ( ($HK:6996) ) just unveiled an update. Antengene Corporation Limited has scheduled a board meeting...

21d ago

Antengene Updates Board Composition and Committee Roles

Antengene Corporation Limited ( ($HK:6996) ) has issued an announcement. Antengene Corporation Limited announced the current composition of...

29d ago

Antengene Reshapes Leadership Team With CFO Exit and New Executive Appointments

The latest update is out from Antengene Corporation Limited ( ($HK:6996) ). Antengene Corporation Limited announced the resignation...

1M ago

Antengene Signals Major Interim Profit on Oncology Licensing Deals

Antengene Corporation Limited ( ($HK:6996) ) has issued an announcement. Antengene has issued a positive profit alert for...

1M ago

Antengene Secures USD60 Million Upfront from UCB for ATG-201 License

Antengene Corporation Limited ( ($HK:6996) ) has issued an announcement. Antengene Corporation Limited announced it has received a...

2M ago

Antengene Launches HK$50 Million Share Buyback Plan

The latest announcement is out from Antengene Corporation Limited ( ($HK:6996) ). Antengene Corporation Limited has announced a...

2M ago

Antengene Out-Licenses ATG-106 to K2 Therapeutics in Potential US$1.9 Billion TCE Deal

Antengene Corporation Limited ( ($HK:6996) ) has issued an update. Antengene has entered into an exclusive, sublicensable license...

2M ago

Antengene Reshuffles Joint Company Secretaries to Strengthen Governance Compliance

An announcement from Antengene Corporation Limited ( ($HK:6996) ) is now available. Antengene Corporation Limited announced that Yang...

3M ago

722 FAQ

What was Antengene Corporation Limited’s price range in the past 12 months?

Antengene Corporation Limited lowest stock price was €0.29 and its highest was €0.85 in the past 12 months.

What is Antengene Corporation Limited’s market cap?

Antengene Corporation Limited’s market cap is €269.29M.

When is Antengene Corporation Limited’s upcoming earnings report date?

Antengene Corporation Limited’s upcoming earnings report date is Mar 19, 2027 which is in 200 days.

How were Antengene Corporation Limited’s earnings last quarter?

Antengene Corporation Limited released its earnings results on Aug 21, 2026. The company reported €0.044 earnings per share for the quarter, missing the consensus estimate of €0.047 by -€0.004.

Is Antengene Corporation Limited overvalued?

According to Wall Street analysts Antengene Corporation Limited’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Antengene Corporation Limited pay dividends?

Antengene Corporation Limited does not currently pay dividends.

What is Antengene Corporation Limited’s EPS estimate?

Antengene Corporation Limited’s EPS estimate is 0.02.

How many shares outstanding does Antengene Corporation Limited have?

Antengene Corporation Limited has 679,446,660 shares outstanding.

What happened to Antengene Corporation Limited’s price movement after its last earnings report?

Antengene Corporation Limited reported an EPS of €0.044 in its last earnings report, missing expectations of €0.047. Following the earnings report the stock price went down -3.333%.

Which hedge fund is a major shareholder of Antengene Corporation Limited?

Currently, no hedge funds are holding shares in DE:722

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Antengene Corporation Limited

Antengene Corporation Limited, a biopharmaceutical firm, is dedicated to developing advanced oncology treatments primarily within the Chinese market. Its active clinical development pipeline includes several innovative compounds. Among these, ATG-016, a next-generation XPO1 inhibitor, is currently undergoing Phase I/II clinical trials for individuals with solid tumors. ATG-527 (Verdinexor) has successfully completed its Phase I evaluation for chronic human viral infections. The company is also advancing ATG-019, a dual PAK4/NAMPT inhibitor targeting non-Hodgkin's lymphoma and advanced solid tumors, and ATG-017, an ERK1/2 inhibitor designed for treating advanced solid tumors and hematologic malignancies. Additionally, ATG-010 (selinexor) is a SINE compound that modulates XPO1. ATG-101, a bispecific PD-L1/4-1BB antibody, is in Phase I studies for patients with metastatic/advanced solid tumors and B-cell non-Hodgkin's lymphoma. Completing its clinical-stage assets is ATG-008 (onatasertib), an orally delivered mTOR kinase inhibitor aimed at solid tumors exhibiting specific genetic alterations like NFE2L2, STK11, and RICTOR. In its earlier, pre-clinical research phase, Antengene is exploring ATG-037, a CD73 inhibitor for advanced or metastatic solid tumors; ATG-018, an ATR inhibitor; ATG-022, a Claudin 18.2 antibody-drug conjugate; ATG-031, a CD24 antibody; ATG-027, a B7H3/PD-L1 bispecific antibody; ATG-032, a LILRB antibody; and ATG-041, an Axl-Mer inhibitor. Founded in 2016, the company maintains its headquarters in Shanghai, China.

Antengene Corporation Limited (722) Earnings & Revenues

Historic Earnings Reports

722 Stock 12 Month Forecast

Average Price Target

€1.17

▲(120.13% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"€2","-1":"-€1","-0.25":"-€0.25","0.5":"€0.5","1.25":"€1.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":1.166689,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€1.17</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1.166689,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€1.17</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1.166689,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€1.17</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,-0.25,0.5,1.25,2],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.414,0.47189915384615383,0.5297983076923077,0.5876974615384616,0.6455966153846154,0.7034957692307693,0.7613949230769231,0.819294076923077,0.8771932307692308,0.9350923846153847,0.9929915384615386,1.0508906923076924,1.1087898461538463,{"y":1.166689,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.414,0.47189915384615383,0.5297983076923077,0.5876974615384616,0.6455966153846154,0.7034957692307693,0.7613949230769231,0.819294076923077,0.8771932307692308,0.9350923846153847,0.9929915384615386,1.0508906923076924,1.1087898461538463,{"y":1.166689,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.414,0.47189915384615383,0.5297983076923077,0.5876974615384616,0.6455966153846154,0.7034957692307693,0.7613949230769231,0.819294076923077,0.8771932307692308,0.9350923846153847,0.9929915384615386,1.0508906923076924,1.1087898461538463,{"y":1.166689,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.515,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.73,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.7,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.54,"date":1761955200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.468,"date":1764547200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.396,"date":1767225600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.37,"date":1769904000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.306,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.56,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.53,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.406,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.374,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.414,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >